SEC Company Response from Lineage Cell Therapeutics, Inc. (LCTX) (CIK 0000876343) (LCTX) — Jun 27, 2017
Lineage Cell Therapeutics, Inc. (LCTX) (CIK 0000876343)
Date: June 27, 2017 · CIK: 0000876343 · Accession: 0001140361-17-026146
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-218807
Letter
VIA EDGAR Division of Corporation Finance Request for Acceleration Acceleration Request Request Date: June 28, 2017 Request Time: 9:30 a.m. Eastern Time (or as soon thereafter as practicable)
Dear Ms. Yale:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, BioTime, Inc., a California corporation (the “Registrant”), hereby respectfully requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-218807), to become effective at 9:30 a.m. Eastern Time on June 28, 2017, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff (the “Staff”) of the Commission. The Registrant hereby authorizes Michael A. Hedge or Alexa M. Ekman of K&L Gates LLP, counsel to the Company, to orally modify or withdraw this request for acceleration.
The Registrant requests that it be notified of such effectiveness by a telephone call to Michael A. Hedge at (949) 623-3519, or in his absence, Alexa M. Ekman at (949) 623-3603.
Sincerely,
BIOTIME, INC.
Show Raw Text
CORRESP 1 filename1.htm BioTime, Inc. 1010 Atlantic Avenue, Suite 102 Alameda, California 94501 June 26, 2017 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Dorrie Yale Re: BioTime, Inc. Registration Statement on Form S-3 File No. 333-218807 Request for Acceleration Acceleration Request Request Date: June 28, 2017 Request Time: 9:30 a.m. Eastern Time (or as soon thereafter as practicable) Dear Ms. Yale: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, BioTime, Inc., a California corporation (the “Registrant”), hereby respectfully requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-218807), to become effective at 9:30 a.m. Eastern Time on June 28, 2017, or as soon thereafter as practicable, or at such later time as the Registrant or its counsel may orally request via telephone call to the staff (the “Staff”) of the Commission. The Registrant hereby authorizes Michael A. Hedge or Alexa M. Ekman of K&L Gates LLP, counsel to the Company, to orally modify or withdraw this request for acceleration. The Registrant requests that it be notified of such effectiveness by a telephone call to Michael A. Hedge at (949) 623-3519, or in his absence, Alexa M. Ekman at (949) 623-3603. Sincerely, BIOTIME, INC. By: /s/ Michael D. West, Ph.D. Michael D. West, Ph.D. Co-Chief Executive Officer cc: Russell Skibsted, BioTime, Inc. Stephana Patton, BioTime, Inc. Michael A. Hedge, K&L Gates LLP Alexa M. Ekman, K&L Gates LLP